EUVIMEDEUVIMED entdecken
Open Access

The Effect of Pexidartinib on Neuropathic Pain via Influences on Microglia and Neuroinflammation in Mice

Liuyue Yang, Ashley Gomm, Ping Bai, Weihua Ding, Rudolph E Tanzi, Changning Wang, Shiqian Shen, Can Zhang

Anesthesia & Analgesia · 2025

DOI: 10.1213/ane.0000000000007239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anesthesia & Analgesia, 2025. Verfasst von Liuyue Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Microglia, Neuralgia, Aminopyridines, Neuroinflammatory Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Health, NIA NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chronic pain is a debilitating medical condition that lacks effective treatments. Increasing evidence suggests that microglia and neuroinflammation underlie pain pathophysiology, which therefore supports a potential strategy for developing pain therapeutics. Here, our study is testing the hypothesis that the promise of pain amelioration can be achieved using the small-molecule pexidartinib (PLX-3397), a previously food and drug administration (FDA)-approved cancer medicine and a colony-stimulating factor-1 receptor (CSF-1R) inhibitor that display microglia-depleting properties. METHOD: We used the previously reported chronic constriction injury (CCI) mouse model, in which PLX-3397 or vehicle was orally administrated to mice daily for 21 days, then applied to the CCI model, followed by PLX-3397 or vehicle administration for an additional 28 days. Additionally, we examined microglia-related neuroinflammation markers using positron emission tomography (PET) neuroimaging and immunofluorescence (IF). RESULTS: We showed that PLX-3397 significantly ameliorated pain-related behavioral changes throughout the entire experimental period after CCI (vehicle versus PLX-3397 at day 14, effect size: 2.57, P = .002). Microglia changes were first analyzed by live-animal PET neuroimaging, revealing PLX-3397-associated reduction of microglia by probing receptor-interacting serine/threonine-protein kinase 1 (RIPK1), a protein primarily expressed in microglia, which were further corroborated by postmortem immunohistochemistry (IHC) analysis using antibodies for microglia, including ionized Ca 2+ binding adaptor molecule 1 (Iba-1) (somatosensory cortex, hindlimb area; vehicle versus PLX-3397, effect size 3.6, P = .011) and RIPK1 (somatosensory cortex, hindlimb area; vehicle versus PLX-3397, effect size 2.9, P = .023. The expression of both markers decreased in the PLX-3397 group. Furthermore, we found that PLX-3397 led to significant reductions in various proteins, including inducible nitric oxide synthase (iNOS) (somatosensory cortex, hindlimb area; vehicle versus PLX-3397, effect size: 2.3, P = .048), involved in neuroinflammation through IHC. CONCLUSIONS: Collectively, our study showed PLX-3397-related efficacy in ameliorating pain linked to the reduction of microglia and neuroinflammation in mice. Furthermore, our research provided new proof-of-concept data supporting the promise of testing PLX-3397 as an analgesic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicrogliaNeuralgiaAminopyridinesNeuroinflammatory DiseasesPyrrolesAnimalsMaleMiceMice, Inbred C57BLDisease Models, AnimalBehavior, Animal

Substanzen

pexidartinibAminopyridinesPyrroles

Autor:innen und Institutionen

  • From the Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Genetics and Aging Research Unit, Department of Neurology, McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Boston, Massachuse…
  • Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Förderung

  • National Institute of Health
  • NIA NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Yang, L., Gomm, A., Bai, P., Ding, W., Tanzi, R. E., Wang, C., Shen, S., & Zhang, C. (2025). The Effect of Pexidartinib on Neuropathic Pain via Influences on Microglia and Neuroinflammation in Mice. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000007239

Vancouver

Yang L, Gomm A, Bai P, Ding W, Tanzi RE, Wang C, et al. The Effect of Pexidartinib on Neuropathic Pain via Influences on Microglia and Neuroinflammation in Mice. Anesthesia & Analgesia. 2025. doi:10.1213/ane.0000000000007239

BibTeX
@article{Yang2025,
  author = {Yang, Liuyue and Gomm, Ashley and Bai, Ping and Ding, Weihua and Tanzi, Rudolph E and Wang, Changning and Shen, Shiqian and Zhang, Can},
  title = {The Effect of Pexidartinib on Neuropathic Pain via Influences on Microglia and Neuroinflammation in Mice},
  journal = {Anesthesia & Analgesia},
  year = {2025},
  doi = {10.1213/ane.0000000000007239}
}
Kostenlos starten →